{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24"}]}],"title":"Percentage with Dose Reductions Required"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}],"title":"Percentage Receiving < 4 Cycles of Therapy"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.79"}]}],"title":"Percentage Who Discontinued After Only 1 Cycle"},{"categories":[{"measurements":[{"groupId":"OG000","value":"48"}]}],"title":"Percentage with Grade 3/4 Neutropenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}],"title":"Percentage with Grade 3/4 Fatigue"}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"}],"units":"Participants"}],"description":"Tolerability of full dose Revlimid® with full dose Doxil® in combination with reduced schedule dexamethasone was to be assessed during Cycle 1 and at the start of Cycle 2 using, whenever possible, the National Cancer Institute Common Terminology for Adverse Events (NCI CTCAE) v3.0.\n\nDue to increased neutropenia and fatigue, toxicities were reviewed after the first 29 participants were enrolled.","groups":[{"description":"Induction Phase for First 29 Participants\n\nPatients received lenalidomide 25 mg orally on days 1-21, dexamethasone 40 mg orally on days on 1-4, and Pegylated Liposomal Doxorubicin (PLD) 40 mg/m\\^2 intravenously on day 1.","id":"OG000","title":"Induction at Initial Full Dose"}],"paramType":"NUMBER","populationDescription":"First 29 participants with the PLD starting dose of PLD 40 mg/m\\^2, due to increased neutropenia and fatigue.","reportingStatus":"POSTED","timeFrame":"24 Months","title":"Occurrence of Induction Toxicities","type":"SECONDARY","unitOfMeasure":"percentage of participants"}